Arakawa F, Yamamoto T, Kanda H, Watanabe T, Kuroki M
First Department of Biochemistry, School of Medicine, Fukuoka University, Japan.
Hybridoma. 1999 Apr;18(2):131-8. doi: 10.1089/hyb.1999.18.131.
Mouse monoclonal antibody (MAb) FU-MK-1, raised against a human gastric adenocarcinoma, recognizes a transmembrane antigen, GA733-2, present on most adenocarcinomas and seems to be of potential utility for immunodiagnosis and immunotherapy of those cancers. However, an inherent problem in their in vivo application is the human anti-mouse antibody response. In this study, we cloned and sequenced the variable region genes of the heavy and light chains (V(H) and Vkappa) of FU-MK-1 using the reverse transcription-polymerase chain reaction method. Then, we constructed a mouse/human chimeric antibody, designated as Ch FU-MK-1, by fusing the FU-MK-1 V(H) and Vkappa genes to the human Cgamma1 and Ckappa genes, respectively, and by ligating the chimeric H and L chain genes to each other in a mammalian cell expression vector. The final gene construct was transfected into mouse non-Ig-producing hybridoma cells by electroporation. The Ch FU-MK-1 antibody thus prepared bound to human adenocarcinoma cells and competitively inhibited the binding of the parental FU-MK-1 to the adenocarcinoma cells. Ch FU-MK-1 also showed a potent antibody-dependent cell-mediated cytotoxicity (ADCC) with human peripheral blood mononuclear cells as effectors against the adenocarcinoma cells, indicating that this chimeric antibody seems to be suitable for in vivo therapeutic approaches.
针对人胃腺癌产生的小鼠单克隆抗体(MAb)FU-MK-1可识别一种跨膜抗原GA733-2,该抗原存在于大多数腺癌中,似乎对这些癌症的免疫诊断和免疫治疗具有潜在应用价值。然而,其体内应用存在一个固有问题,即人抗小鼠抗体反应。在本研究中,我们使用逆转录-聚合酶链反应方法克隆并测序了FU-MK-1重链和轻链(V(H)和Vκ)的可变区基因。然后,我们通过将FU-MK-1的V(H)和Vκ基因分别与人Cγ1和Cκ基因融合,并在哺乳动物细胞表达载体中将嵌合的重链和轻链基因彼此连接,构建了一种小鼠/人嵌合抗体,命名为Ch FU-MK-1。最终的基因构建体通过电穿孔转染到小鼠不产生免疫球蛋白的杂交瘤细胞中。由此制备的Ch FU-MK-1抗体与人腺癌细胞结合,并竞争性抑制亲本FU-MK-1与腺癌细胞的结合。Ch FU-MK-1还对人外周血单个核细胞作为效应细胞针对腺癌细胞表现出强大的抗体依赖性细胞介导的细胞毒性(ADCC),表明这种嵌合抗体似乎适用于体内治疗方法。